Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

Capricor Therapeutics presented updated deramiocel data for Duchenne muscular dystrophy, including two-year open-label extension results from its Phase III HOPE-3 study. The company also submitted additional statistical analyses to the FDA; the article provides no efficacy figures or regulatory outcome.